Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01914952 · ClinicalTrials.gov registry record · NA
Alternate Dosing Strategies for Beta-hydroxy-beta-methylbutyrate (HMB) Supplementation: Effect on Plasma HMB Responses
A NA study, sponsored by Metabolic Technologies.
- Completed
- Registry status
- NA
- Development phase
- 11
- Enrollment target
NCT01914952: Completed NA study, sponsored by Metabolic Technologies.
NCT01914952 is a NA study that has completed, run by Metabolic Technologies. The registered enrollment target is 11 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01914952, a NA study, has completed, sponsored by Metabolic Technologies.
- COMPLETED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the rise in plasma Beta-hydroxy-beta-methylbutyrate (HMB) after the dietary supplement has been administered in different forms. Prior studies have indicated that form of administration affects bioavailability of the HMB supplement. Therefore the current study will examine the bioavailability of a single dose of HMB given as: * 1.0g CaHMB in gelatin capsule * 0.8 g HMB free acid in a gelcap * 0.8 g HMB free acid in water * 1.0 g CaHMB in water * 0.8 g HMB free acid The randomized study will be a crossover design and each study subject will undergo the experimental protocol for each of the supplementation forms. Because of the different administration forms, the study will be an open label study. Briefly, the fasted participants will report to the laboratory in the morning. After an initial blood sample is taken, the dose of HMB will be administered. Blood will then be samples at 2, 5, 10, 15, 25, 35, 45, 60, 90, 120, 180, 360, 720, and 1440 min post administration. A 24 h complete urine collection will also be performed. Participants will be given a light sack lunch 4 h after administration of the dosage and will remain at the laboratory through the 360 min sampling. Participants will then be allowed to leave the laboratory and return for the 720 min sampling after which the participants can eat an normal evening meal. Participants will return to the laboratory fasted the next morning for the final sample. A minimum 48 h washout period will be required before the next dosage form is administered and the process repeated.
Interventions
- DIETARY_SUPPLEMENT CaHMB capsule
- DIETARY_SUPPLEMENT HMB free acid gelcap
- DIETARY_SUPPLEMENT HMB free acid mixed in water
- DIETARY_SUPPLEMENT CaHMB in water
- DIETARY_SUPPLEMENT HMB free acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-05 |
| Phase | NA |
What the finished NCT01914952 record still lists
NCT01914952 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 5 interventions - of which CaHMB capsule is the first listed.
NCT01914952 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01914952 about?
NCT01914952 is a clinical study titled "Alternate Dosing Strategies for Beta-hydroxy-beta-methylbutyrate (HMB) Supplementation: Effect on Plasma HMB Responses". The purpose of this study is to examine the rise in plasma Beta-hydroxy-beta-methylbutyrate (HMB) after the dietary supplement has been administered in different forms. Prior studies have indicated that form of administration affects bioavailability of the HMB supplement. Therefore the current study...
What is the current status of trial NCT01914952?
This trial is currently completed. It is a NA study. The enrollment target is 11 participants. The study started on 2013-05. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01914952?
The interventions under investigation include: CaHMB capsule (DIETARY_SUPPLEMENT), HMB free acid gelcap (DIETARY_SUPPLEMENT), HMB free acid mixed in water (DIETARY_SUPPLEMENT), CaHMB in water (DIETARY_SUPPLEMENT), HMB free acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01914952?
This trial is sponsored by Metabolic Technologies, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01914952's enrollment target sits among peer trials
11 1927th of 2000 higher than 74 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia